Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

Posted:
3
March 2014

Moxifloxacin is used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. A meal shortens the QT interval and in some instances it is desirable to use moxifloxacin after a meal which may affect PK or PD or both; however there is no published data.Based on a recent peer-reviewed paper published in January 2014 in the British Journal of Clinical Pharmacology Richmond Pharmacology will present its latest findings as an encore poster presentation at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), taking place 18th to 22nd March, in Atlanta, Georgia.Join Richmond Pharmacology s Dr Jorg Taubel on 21st March between 11h45 and 13h15 (poster number EII-001) for insight into this new area of research.Read Full PaperView Meeting Program

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more